141 related articles for article (PubMed ID: 21873171)
1. KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines.
Yoshida Y; Tsunoda T; Doi K; Tanaka Y; Fujimoto T; Machida T; Ota T; Koyanagi M; Takashima Y; Sasazuki T; Kuroki M; Iwasaki A; Shirasawa S
Anticancer Res; 2011 Jul; 31(7):2535-9. PubMed ID: 21873171
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific manner in colorectal cancer cells.
Tsunoda T; Takashima Y; Yoshida Y; Doi K; Tanaka Y; Fujimoto T; Machida T; Ota T; Koyanagi M; Kuroki M; Sasazuki T; Shirasawa S
Anticancer Res; 2011 Jul; 31(7):2453-9. PubMed ID: 21873159
[TBL] [Abstract][Full Text] [Related]
3. Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.
Kang W; Tong JH; Chan AW; Zhao J; Wang S; Dong Y; Sin FM; Yeung S; Cheng AS; Yu J; To K
Oncol Rep; 2014 Jun; 31(6):2579-86. PubMed ID: 24756820
[TBL] [Abstract][Full Text] [Related]
4. Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair.
Lu AG; Feng H; Wang PX; Han DP; Chen XH; Zheng MH
World J Gastroenterol; 2012 Sep; 18(34):4704-13. PubMed ID: 23002339
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a Three-dimensional Floating Cell Culture System for Screening Drugs Targeting KRAS-mediated Signaling Molecules.
Tsunoda T; Ishikura S; Doi K; Iwaihara Y; Hidesima H; Luo H; Hirose Y; Shirasawa S
Anticancer Res; 2015 Aug; 35(8):4453-9. PubMed ID: 26168486
[TBL] [Abstract][Full Text] [Related]
6. KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells.
Ota T; Doi K; Fujimoto T; Tanaka Y; Ogawa M; Matsuzaki H; Kuroki M; Miyamoto S; Shirasawa S; Tsunoda T
Anticancer Res; 2012 Jun; 32(6):2271-5. PubMed ID: 22641662
[TBL] [Abstract][Full Text] [Related]
7. ALPK2 is crucial for luminal apoptosis and DNA repair-related gene expression in a three-dimensional colonic-crypt model.
Yoshida Y; Tsunoda T; Doi K; Fujimoto T; Tanaka Y; Ota T; Ogawa M; Matsuzaki H; Kuroki M; Iwasaki A; Shirasawa S
Anticancer Res; 2012 Jun; 32(6):2301-8. PubMed ID: 22641666
[TBL] [Abstract][Full Text] [Related]
8. Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.
Liu X; Zhang H; Lai L; Wang X; Loera S; Xue L; He H; Zhang K; Hu S; Huang Y; Nelson RA; Zhou B; Zhou L; Chu P; Zhang S; Zheng S; Yen Y
Clin Sci (Lond); 2013 May; 124(9):567-78. PubMed ID: 23113760
[TBL] [Abstract][Full Text] [Related]
9. ETV4 plays a role on the primary events during the adenoma-adenocarcinoma progression in colorectal cancer.
Fonseca AS; Ramão A; Bürger MC; de Souza JES; Zanette DL; de Molfetta GA; de Araújo LF; de Barros E Lima Bueno R; Aguiar GM; Plaça JR; Alves CP; Dos Santos ARD; Vidal DO; Silva GEB; Panepucci RA; Peria FM; Feres O; da Rocha JJR; Zago MA; Silva WA
BMC Cancer; 2021 Mar; 21(1):207. PubMed ID: 33648461
[TBL] [Abstract][Full Text] [Related]
10. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
12. The interplay between epigenetic silencing, oncogenic KRas and HIF-1 regulatory pathways in control of BNIP3 expression in human colorectal cancer cells.
Swiderek E; Kalas W; Wysokinska E; Pawlak A; Rak J; Strzadala L
Biochem Biophys Res Commun; 2013 Nov; 441(4):707-12. PubMed ID: 24211581
[TBL] [Abstract][Full Text] [Related]
13. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
Fang Z; Gong C; Liu H; Zhang X; Mei L; Song M; Qiu L; Luo S; Zhu Z; Zhang R; Gu H; Chen X
Biochem Biophys Res Commun; 2015 Aug; 464(2):407-15. PubMed ID: 26093293
[TBL] [Abstract][Full Text] [Related]
14. CREB1 directly activates the transcription of ribonucleotide reductase small subunit M2 and promotes the aggressiveness of human colorectal cancer.
Fang Z; Lin A; Chen J; Zhang X; Liu H; Li H; Hu Y; Zhang X; Zhang J; Qiu L; Mei L; Shao J; Chen X
Oncotarget; 2016 Nov; 7(47):78055-78068. PubMed ID: 27801665
[TBL] [Abstract][Full Text] [Related]
15. P21WAF1/CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis.
Mitomi H; Ohkura Y; Fukui N; Kanazawa H; Kishimoto I; Nakamura T; Yokoyama K; Sada M; Kobayashi K; Tanabe S; Saigenji K
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):883-9. PubMed ID: 17873613
[TBL] [Abstract][Full Text] [Related]
16. Krüppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis.
Nandan MO; McConnell BB; Ghaleb AM; Bialkowska AB; Sheng H; Shao J; Babbin BA; Robine S; Yang VW
Gastroenterology; 2008 Jan; 134(1):120-30. PubMed ID: 18054006
[TBL] [Abstract][Full Text] [Related]
17. Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2.
Mologni L; Dekhil H; Ceccon M; Purgante S; Lan C; Cleris L; Magistroni V; Formelli F; Gambacorti-Passerini CB
Cancer Res; 2010 Sep; 70(18):7253-63. PubMed ID: 20823162
[TBL] [Abstract][Full Text] [Related]
18. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
19. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer.
Datta D; Flaxenburg JA; Laxmanan S; Geehan C; Grimm M; Waaga-Gasser AM; Briscoe DM; Pal S
Cancer Res; 2006 Oct; 66(19):9509-18. PubMed ID: 17018607
[TBL] [Abstract][Full Text] [Related]
20. A MYBL2 complex for RRM2 transactivation and the synthetic effect of MYBL2 knockdown with WEE1 inhibition against colorectal cancer.
Liu Q; Guo L; Qi H; Lou M; Wang R; Hai B; Xu K; Zhu L; Ding Y; Li C; Xie L; Shen J; Xiang X; Shao J
Cell Death Dis; 2021 Jul; 12(7):683. PubMed ID: 34234118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
